nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo searchdiv qikanlogo popupnotification paper paperNew
2025, 01, v.53 15-19
从肠黏膜屏障的角度探讨玉屏风散干预慢性阻塞性肺疾病的机制
基金项目(Foundation): 广东省中医药局科研项目(20221345)
邮箱(Email): 93519443@qq.com;
DOI:
摘要:

目的:探讨玉屏风散在慢性阻塞性肺疾病(COPD)治疗中的作用及其机制。方法:选取2023年2月至2024年7月深圳市罗湖区人民医院就诊的60例门诊或住院的COPD患者,随机分为对照组和观察组,每组30例,对照组接受西医常规治疗,观察组在西医常规治疗基础上加用玉屏风颗粒。对比两组治疗前后的临床症状改善情况、肺功能指标、血清中的DAO、D-乳酸、LPS、Occludin和ZO-1水平以及肠道菌群结构的变化,评估玉屏风颗粒的疗效和安全性。结果:玉屏风颗粒能够显著改善COPD患者的临床症状和肺功能(均P<0.05),降低血清中的DAO、D-乳酸、LPS、Occludin和ZO-1水平(治疗前11.79±3.20 ng/mL,15.56±6.08μg/mL,15.45±1.85ng/mL,4.15±1.11 ng/mL,2.55±1.77 ng/mL,治疗后10.09±2.87 ng/mL,13.40±6.11μg/mL,15.15±1.86 ng/ml,3.75±0.71 ng/mL,2.20±1.47 ng/mL,均P<0.05)。结论:玉屏风能改善COPD患者肺功能,调节肠道菌群结构,改善肠黏膜屏障功能,且药物安全性良好,值得推广应用。

Abstract:

Objective:To explore the role and mechanism of Yu Pingfeng Powder in the treatment of Chronic Obstructive Pulmonary Disease(COPD).Methods:A total of 60 outpatients or inpatients with COPD who visited the People′s Hospital of Luohu District,Shenzhen,from February 2023 to July 2024 were randomly divided into a control group and an observation group,with 30 cases in each group. The control group received conventional Western medicine treatment,while the observation group received Yu Pingfeng Granules in addition to the conventional Western medicine treatment. The clinical symptom improvement,pulmonary function indicators,levels of DAO,D-lactate,LPS,Occludin,and ZO-1 in serum,and changes in gut microbiota structure were compared between the two groups before and after treatment to evaluate the efficacy and safety of Yu PingfengGranules.Results:Yu Pingfeng Granules significantly improved the clinical symptoms and pulmonary function of COPD patients(all P<0.05),reduced the levels of DAO,D-lactate,LPS,Occludin,and ZO-1 in serum(pre-treatment levels of DAO,D-lactate,Occludin,ZO-1,and LPS were 11.79±3.20 ng/mL,15.56±6.08 μg/mL,4.15±1.11 ng/mL,2.55±1.77 ng/mL,and 15.45±1.85 ng/mL,respectively,and post-treatment levels were 10.09±2.87 ng/mL,13.40±6.11 μg/mL,3.75±0.71 ng/mL,2.20±1.47ng/mL,and 15.15±1.86 ng/mL,respectively,all P<0.05).Conclusion:Yu Pingfeng can improve pulmonary function in COPD patients,regulate gut microbiota structure,and enhance intestinal mucosal barrier function,with good drugsafety. It is worthy of promotion and application.

参考文献

[1] Adeloye D,Song PG,Zhu YJ,et al.Global,regional,and national prevalence of,and risk factors for,chronic obstructive pulmonary disease(copd)in 2019:a systematic review and modelling analysis[J]. Lancet Respir Med,2022,10(5):447-458.

[2] An J,Liu YQ,Wang YQ,et al. The role of intestinal mucosal barrier in autoimmune disease:a potential target[J]. Front Immunol,2022,13:871713.

[3]王艳磊,赵宇,袁海硕,等.肠黏膜屏障功能客观评价指标的研究和应用现状[J].医学研究与战创伤救治,2024,37(6):669-672.

[4]黎学聪,王昭灿,刘穗,等.玉屏风散化裁联合沙美特罗替卡松治疗慢性阻塞性肺疾病[J].世界中医药,2023,18(18):2645-2650.

[5]陈韵如,龙思丹,杨道文,等.加味玉屏风散联合常规西药治疗慢性阻塞性肺疾病稳定期的系统评价与meta分析[J].海南医学院学报,2020,26(23):1814-1821,1825.

[6]刘海叶,骆姗,贾智玲,等.玉屏风颗粒对慢性阻塞性肺疾病模型大鼠肺泡灌洗液代谢组学及肠道菌群的影响[J].中医杂志,2023,64(20):2116-2124.

[7]杜晓秋,周军,张秋娣.不同评价指标在慢性阻塞性肺疾病患者综合评估中的应用[J].中国全科医学,2016,19(5):511-516.

[8]李东萍,郭明璋,许文涛. 16SrRNA测序技术在肠道微生物中的应用研究进展[J].生物技术通报,2015,31(2):71-77.

[9]江芳超,张积友,郝旭仲,等.老年慢性阻塞性肺疾病患者肠道菌群失调状况及影响因素分析[J].山东中医杂志,2023,42(5):456-464.

[10]王兴鹏,郭传勇.肠道菌群失调诊断治疗建议[J].中华消化杂志,2009(5):335-337.

[11]冯曙平,王戈菲,陈翠,等.玉屏风颗粒对慢性阻塞性肺疾病急性发作期及后续稳定期患者肺功能、CAT评分、免疫功能的影响[J].现代中西医结合杂志,2020,29(36):4020-4023,4028.

[12]梁鹏涛,仇振明,宋丽云,等.基于“肺与大肠相表里”理论探讨肠屏障损伤与慢性阻塞性肺疾病的关系[J].实用中医内科杂志,2024,38(1):16-20.

[13]轩银霜,毛静,卞晴晴,等.调补肺肾三法对慢性阻塞性肺疾病稳定期大鼠肠道黏膜屏障的影响[J].中国病理生理杂志,2023,39(4):705-713.

[14]时晨,林丽丽,谢彤,等.基于“肺-肠”轴探讨肺、肠微生态对肺部疾病的影响[J].南京中医药大学学报,2020,36(2):168-173.

基本信息:

DOI:

中图分类号:R259

引用信息:

[1]杨建波,夏洪涛,王衍华.从肠黏膜屏障的角度探讨玉屏风散干预慢性阻塞性肺疾病的机制[J].广州医科大学学报,2025,53(01):15-19.

基金信息:

广东省中医药局科研项目(20221345)

检 索 高级检索

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文